S&P 500   4,076.57
DOW   34,395.01
QQQ   293.72
Is Apple Going To Rally Into Year End?
Copper Exploration Heating Up (Ad)
25 Ways to Improve Your Financial Situation in 1 Hour
Are the Short Sellers Still Right About Mullen Automotive stock? 
YIKES! 220 Pounds of Graphite in Each EV Battery? (Ad)
La-Z-Boy Reclines To More Comfortable Levels 
Is The Recovery Rally Here For SoFi?
China Threat Triggers Potential Mining Boom for Investors (Ad)
Biden administration presses senators to avert rail strike
Trump Org. defense lawyer scolded for using struck testimony
S&P 500   4,076.57
DOW   34,395.01
QQQ   293.72
Is Apple Going To Rally Into Year End?
Copper Exploration Heating Up (Ad)
25 Ways to Improve Your Financial Situation in 1 Hour
Are the Short Sellers Still Right About Mullen Automotive stock? 
YIKES! 220 Pounds of Graphite in Each EV Battery? (Ad)
La-Z-Boy Reclines To More Comfortable Levels 
Is The Recovery Rally Here For SoFi?
China Threat Triggers Potential Mining Boom for Investors (Ad)
Biden administration presses senators to avert rail strike
Trump Org. defense lawyer scolded for using struck testimony
S&P 500   4,076.57
DOW   34,395.01
QQQ   293.72
Is Apple Going To Rally Into Year End?
Copper Exploration Heating Up (Ad)
25 Ways to Improve Your Financial Situation in 1 Hour
Are the Short Sellers Still Right About Mullen Automotive stock? 
YIKES! 220 Pounds of Graphite in Each EV Battery? (Ad)
La-Z-Boy Reclines To More Comfortable Levels 
Is The Recovery Rally Here For SoFi?
China Threat Triggers Potential Mining Boom for Investors (Ad)
Biden administration presses senators to avert rail strike
Trump Org. defense lawyer scolded for using struck testimony
S&P 500   4,076.57
DOW   34,395.01
QQQ   293.72
Is Apple Going To Rally Into Year End?
Copper Exploration Heating Up (Ad)
25 Ways to Improve Your Financial Situation in 1 Hour
Are the Short Sellers Still Right About Mullen Automotive stock? 
YIKES! 220 Pounds of Graphite in Each EV Battery? (Ad)
La-Z-Boy Reclines To More Comfortable Levels 
Is The Recovery Rally Here For SoFi?
China Threat Triggers Potential Mining Boom for Investors (Ad)
Biden administration presses senators to avert rail strike
Trump Org. defense lawyer scolded for using struck testimony

Acumen Pharmaceuticals - ABOS Stock Forecast, Price & News

$5.82
+0.14 (+2.46%)
(As of 12/1/2022 12:00 AM ET)
Add
Compare
Today's Range
$5.67
$6.00
50-Day Range
$4.44
$10.48
52-Week Range
$3.02
$10.97
Volume
147,006 shs
Average Volume
530,788 shs
Market Capitalization
$235.73 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$16.75

Acumen Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
187.8% Upside
$16.75 Price Target
Short Interest
Healthy
3.14% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.57mentions of Acumen Pharmaceuticals in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($1.01) to ($1.25) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.31 out of 5 stars

Medical Sector

351st out of 1,047 stocks

Biological Products, Except Diagnostic Industry

57th out of 173 stocks

ABOS stock logo

About Acumen Pharmaceuticals (NASDAQ:ABOS) Stock

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.

Receive ABOS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Acumen Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ABOS Stock News Headlines

Earnings Preview: Acumen Pharmaceuticals
See More Headlines
Receive ABOS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Acumen Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ABOS Company Calendar

Last Earnings
11/14/2022
Today
12/02/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/27/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ABOS
Fax
N/A
Employees
14
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$16.75
High Stock Price Forecast
$22.00
Low Stock Price Forecast
$14.00
Forecasted Upside/Downside
+187.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-100,610,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$1.44 million
Book Value
$4.86 per share

Miscellaneous

Free Float
38,599,000
Market Cap
$235.73 million
Optionable
Not Optionable
Beta
-2.00

Key Executives

  • Mr. Daniel J. O'Connell M.B.A. (Age 51)
    CEO, Pres & Director
    Comp: $801.62k
  • Mr. Matt Zuga
    CFO, Chief Bus. Officer & Corp. Sec.
  • Dr. Eric Siemers M.D. (Age 67)
    Chief Medical Officer
    Comp: $460.64k
  • Mr. Russell Barton M.S. (Age 63)
    Chief Operating Officer
  • Mr. Derek M. Meisner Esq. (Age 51)
    J.D., Chief Legal Officer
  • Ms. Robyn Moxon M.A.
    Mang. of Corp. & Clinical Communications
  • Ms. Julie Bockenstette
    Exec. VP & Head of HR
  • Ms. Siew Tin Gan M.S.
    Assistant VP & Head of Clinical Operations
  • Ms. Janice Hitchcock
    VP & Head of Regulatory Affairs
  • Ms. Liean Schenck M.S.
    VP & Head of CMC













ABOS Stock - Frequently Asked Questions

Should I buy or sell Acumen Pharmaceuticals stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Acumen Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ABOS shares.
View ABOS analyst ratings
or view top-rated stocks.

What is Acumen Pharmaceuticals' stock price forecast for 2023?

4 brokers have issued 12 month price targets for Acumen Pharmaceuticals' stock. Their ABOS share price forecasts range from $14.00 to $22.00. On average, they anticipate the company's share price to reach $16.75 in the next year. This suggests a possible upside of 187.8% from the stock's current price.
View analysts price targets for ABOS
or view top-rated stocks among Wall Street analysts.

How have ABOS shares performed in 2022?

Acumen Pharmaceuticals' stock was trading at $6.76 on January 1st, 2022. Since then, ABOS stock has decreased by 13.9% and is now trading at $5.82.
View the best growth stocks for 2022 here
.

Are investors shorting Acumen Pharmaceuticals?

Acumen Pharmaceuticals saw a decline in short interest during the month of November. As of November 15th, there was short interest totaling 775,600 shares, a decline of 24.0% from the October 31st total of 1,020,000 shares. Based on an average daily trading volume, of 1,360,000 shares, the days-to-cover ratio is presently 0.6 days. Currently, 3.1% of the shares of the company are short sold.
View Acumen Pharmaceuticals' Short Interest
.

When is Acumen Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, March 27th 2023.
View our ABOS earnings forecast
.

How were Acumen Pharmaceuticals' earnings last quarter?

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) issued its earnings results on Monday, November, 14th. The company reported ($0.26) earnings per share for the quarter, beating analysts' consensus estimates of ($0.27) by $0.01.

When did Acumen Pharmaceuticals IPO?

(ABOS) raised $125 million in an initial public offering (IPO) on Thursday, July 1st 2021. The company issued 8,333,333 shares at $14.00-$16.00 per share.

What is Acumen Pharmaceuticals' stock symbol?

Acumen Pharmaceuticals trades on the NASDAQ under the ticker symbol "ABOS."

Who are Acumen Pharmaceuticals' major shareholders?

Acumen Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (2.75%), Commodore Capital LP (2.72%), Vanguard Group Inc. (1.61%), Moore Capital Management LP (1.04%), Silverarc Capital Management LLC (1.04%) and Perceptive Advisors LLC (0.99%). Insiders that own company stock include John A Stalfort III, Marc Benioff, Nathan B Fountain, Paul B Manning and Sands Capital Global Venture F.
View institutional ownership trends
.

How do I buy shares of Acumen Pharmaceuticals?

Shares of ABOS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Acumen Pharmaceuticals' stock price today?

One share of ABOS stock can currently be purchased for approximately $5.82.

How much money does Acumen Pharmaceuticals make?

Acumen Pharmaceuticals (NASDAQ:ABOS) has a market capitalization of $235.73 million and generates $1.44 million in revenue each year.

How can I contact Acumen Pharmaceuticals?

The official website for the company is www.acumenpharm.com. The company can be reached via phone at 925-368-8508 or via email at investors@acumenpharm.com.

This page (NASDAQ:ABOS) was last updated on 12/2/2022 by MarketBeat.com Staff